secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001553350-26-000007
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

The Oncology Institute appoints Kim Tzoumakas to Board of Directors
-------------------------------------------------------------------

- Appointed Kim Tzoumakas, CEO of VytlOne National Pharmacy Services, to board effective Feb. 23, 2026.
- Ms. Tzoumakas previously led 21st Century Oncology through a turnaround and strategic sale; serves on multiple healthcare boards.
- She will receive $75k annual cash retainer paid quarterly plus restricted stock units for board service.
- She was not initially assigned to any board committees; term expires at 2027 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000155335026000007/0001553350-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000155335026000007/toi_8k.htm
  HTML page:      https://secwatch.observer/filing/0001553350-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer